ADMA Adma Biologics Earnings and EPS analysis

Relative Growth: Rel. Growth: 49

Relative Strength: Rel. Strength: 10

Relative Valuation: Rel. Valuation: 68

Relative Profitability: Rel. Profitability: 90

EPS in 2026 (TTM): $0.69

Last Report Period Date: Mar 31, 2026

As of July 2026, according to Adma Biologics's current financial statements, the company's 12-month EPS is $0.69. For the year 2025, the company recorded an earnings per share (EPS) of $0.62, which marks a drop compared to its EPS of $0.85 in 2024. Adma Biologics's earnings per share for the quarterly report ending on Mar 31, 2026 reached $0.19.

ADMA earnings history

Historical annual and quarterly earnings per share (EPS) data for Adma Biologics

EPS (TTM)

$0.69

EPS Growth YoY (Quarterly)

72.7%

EPS (Quarterly)

$0.19

EPS Growth (Quarterly)

-9.5%

The annual EPS for the year 2025 was $0.62, a drop of 27.1% from $0.85 in 2024. For the fiscal quarter that ended on Mar 31, 2026, the per-share earnings was $0.19, showing a 72.7% increase from the same quarter last year. For the twelve months ending March 2026, the EPS is $0.69. For the year 2024, the yearly earnings per share was $0.85, marking an increase of 753.8% from 2023.

ADMA earnings chart

ADMA EPS growth history

Earnings per share growth rates over time

EPS Growth YoY (Quarterly)

72.7%

EPS growth YoY

-27.1%

EPS growth 3Y avg

N/A

EPS growth 5Y avg

N/A

During the last 12 months, Adma Biologics has seen an EPS growth of 72.7% (YoY, quarterly).

ADMA Earnings Waterfall

Breakdown of revenue, profit and net income for Adma Biologics

ADMA Earnings vs Peers

What are the earnings of ADMA compared to its peers

Stock name	Price to Earnings	EPS grwoth 1Y	EPS grwoth 3Y	EPS grwoth 5Y
ADMA Adma Biologics Inc	12.97	-27.1%	N/A	N/A
RGEN Repligen Corp	154.78	289.1%	-36.2%	-5.3%
NVAX Novavax Inc	N/A	321.1%	N/A	N/A
CVM Cel Sci Corp	N/A	59%	N/A	N/A

All data is based on quarterly TTM periods, unless otherwise specified.